



August 31, 2022

David Nelson, President & CEO
Noble Pharma, LLC
4602 Domain Dr.
Menomonie, WI 54751

Sent via email to: dnelson@noblepharmallc.com

Dear Petitioner:

Your submission requesting that the Commissioner of the Food and Drug Administration to file an Abbreviated New Animal Drug Application (ANADA) for a different dosage form of an approved pioneer product. The pioneer product (reference product), Cerenia® (maropitant citrate) Tablet, approved under NADA 141 – 262 for dogs was received and processed under CFR 10.30 by this office on 08/31/2022.

It was assigned docket number FDA-2022-P-2076. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the suitability petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen Malvin
Acting Director
Dockets Management Staff
FDA/Office of Operations (OO)